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The present research work was envisaged to develop bilayer tablets to improve therapeutic efficacy 
of antibiotic combination for the treatment of sexually transmitted diseases. The combination of two 
antibiotics i.e. cefixime trihydrate and ofloxacin were used for the preparation of bilayer tablets which 
act against genito-urinary infections. The formulations comprise of cefixime trihydrate as immediate 
release layer formulated using different superdisintegrants and ofloxacin as extended release layer 
containing HPMC K100M. Evaluation of bilayer tablets were performed for the immediate release 
cefixime layer and sustain release ofloxacin layer with optimization of excipients. The immediate release 
layer of cefixime showed complete release within 30 min and ofloxacin release was extended up to 24 
hours. The similarity factor value of ofloxacin sustained release layer was found to be 87.01 for initial 
and 80.35 after 3 months stability when compared with marketed reference product. The present study 
revealed that cefixime trihydrate and ofloxacin bilayer tablets were successfully developed for the use 
against sexually transmitted infections.
Uniterms: Sexually transmitted diseases/treatment. Bilayer tablets. Cefixime trihydrate. Ofloxacin.
INTRODUCTION
The curable sexually transmitted diseases (STDs) 
are the major public health problems worldwide which 
lead to illness with significant health, social and economic 
consequences, but except HIV no particular attention has 
been given to the prevalence of other infections (Parashar 
et al., 2006; Tree, Morse, 1995; WHO, 2002). It can 
lead to long-term, serious complications and sequelae 
(Robert et al., 1999). In the year 2006, about 85% of 
the HIV infections have spread due to STD patients, 
which is alarming. STDs are among the most common 
infectious diseases. Annually, an estimated 19.7 million 
sexually transmitted infections occur in the United 
States alone. Worldwide, an estimated 499 million cases 
of chlamydia, gonorrhea, syphilis, and trichomoniasis 
occur each year. Some STDs are more prevalent in 
developing countries (chancroid, lymphogranuloma 
venereum [LGV], granuloma inguinale [donovanosis]) 
or in specific regions (gonorrhea with treatment failure 
and decreased susceptibility to cephalosporins in Asia) 
and may be imported into other countries by travelers 
returning from such locales. (Kidd, Workowski, 2016). 
There are various problems with the treatment of sexually 
transmitted disease (STDs) like increasing widespread 
resistance against individual drug, limited alternatives 
in pregnancy or allergy, lack of single agents possessing 
a broad spectrum of activity against multiple genital 
pathogens and higher dose of drug required for treatment 
with frequent dosing (Handsfield 1986; Steen et al., 2012).
Fixed dose combination therapy has various 
advantages over conventional monotherapy such as 
simpler dosage schedule leading to improved patient 
compliance and therefore improved treatment outcomes, 
reduced side effects, reduced development of resistance 
in the case of antimicrobials and potentially lower cost of 
manufacturing, handling , packing and shipping compared 
to the costs of producing separate products (Sica, 1994).
The conventional dosage form produces wide fluctuation 
in drug concentration in the blood stream which led to the 
concept of sustained drug delivery. The goal in designing 
sustained delivery systems is to reduce the frequency of the 
dosing or to increase effectiveness of the drug or providing 
uniform delivery of drug.
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The present research was carried out with the 
aim of developing bilayer tablets of cefixime trihydrate 
and ofloxacin for the treatment of sexually transmitted 
disease (STDs). Cefixime trihydrate and ofloxacin 
were selected as a combination of drugs against STDs 
since this combination was widely used in treatment 
of uncomplicated urethral, endocervical and rectal 
infections caused by susceptible Neisseria gonorrhea 
and Chlamydia trachomatis (Schmidt, Charles, 1995; 
Bennett, Brown, 2008). Literature studies revealed 
that extensive work have been done on individual 
drugs i.e. ofloxacin sustained release formulation using 
HPMC K100M (Chavanpatil et al., 2005), methacrylic 
acid copolymers (Yue et al., 2008) and cefixime 
trihydrate immediate release tablets using different 
superdisintegrants (Remya et al., 2010). But no work 
has been reported yet on the use of these two drugs in 
combinations as bilayer tablets. Hence, it was thought 
worthwhile to formulate a novel bilayer tablet comprising 
of cefixime trihydrate as immediate release layer and 
ofloxacin as sustained release layer. So as to reduce the 
total dose of drug need to be taken twice in a day and 
dosing frequency. Dose reduction by giving maintainence 
dose of ofloxacin will eventually reduce adverse effect, 
whereas reduction in dosing frequency will lead to 
patient compliance. The effect of varying concentration 
of different superdisintegrants on disintegration and 
dissolution of cefixime trihydrate immediate release 
layer was evaluated. Also, HPMC K100M was evaluated 
as release modifying sustained release excipient in the 
development of sustained release layer. Ofloxacin release 
can be extended up to 24 hours since, the average transit 
time through just the large intestine (colon) was 40 hours 
(Mayoclinic). The compatibility of drugs with excipients 
was studied by FT-IR. The formulated bilayer tablets 
were compared with the marketed formulations to study 
the similarity factor of release profiles. Such bilayer 
tablet having varying release pattern of antibiotics has 
not been reported.
MATERIAL AND METHODS
Materials
Cefixime trihydrate and ofloxacin were received as 
research samples from Zim Laboratories Ltd. (Nagpur, 
India) and Vama Pharma (Nagpur, India) respectively. 
Hydroxypropyl methyl cellulose (HPMC K100M), 
Polyplasdone XL (Crospovidone) and Glycolys (sodium 
starch glycolate) were generously gifted by Colorcon Asia 
Pvt. Ltd. (Goa, India), International Specialty Product Ltd. 
(Mumbai, India) and Roquette India Pvt. Ltd. (Mumbai, 
India) respectively. Ac-Di-Sol (Croscarmellose sodium) 
and Avicel (PH 101 and PH 102) (Microcrystalline 
cellulose) were supplied by Signet Chemical Corporation 
Pvt. Ltd. (Mumbai, India). Lactose monohydrate was 
purchased from LobaChemie Pvt. Ltd. (Mumbai, India). 
Aerosil 200P (Colloidal silicon dioxide) was obtained 
from Evonik Degussa India Pvt. Ltd. (Mumbai, India). 
All other chemicals and reagents were of analytical grade. 
Table I gives the physicochemical parameters of cefixime 
trihydrate ofloxacin.
METHODS
Preformulation studies
To check the drug-drug and drug-excipient 
interactions, preformulation studies were performed. 
Drugs alone, in combination and along with excipients 
proposed to be used were filled in amber colored vials 
sealed with bromo butyl rubber stoppers and kept in 
environmental stability chamber (Remi Lab, Mumbai, 
India) for accelerated stability condition at 40 ± 2 oC 
temperature and 75 ± 5 % relative humidity for a period 
of 30 days. Infra-red spectra of samples were obtained 
with FT-IR spectrophotometer (FTIR-8001, Shimadzu, 
Japan) operated with omnic software and compared with 
the initial spectra of drugs.
Development of Cefixime trihydrate immediate 
release (IR) tablets
The composition of various batches is given in 
Table II. Different batches of cefixime trihydrate IR 
tablets were formulated using different superdisintegrants 
in varying concentration of 3, 5 and 7%w/w. Cefixime 
trihydrate and excipients were passed through ASTM 
(American Society for Testing and Materials) 40 mesh 
sieve (425 µ) and dry blended for 10 min in double 
cone blender at 14 ± 2 rpm. Aerosil 200P (0.5%w/w) 
and magnesium stearate (0.5%w/w) were sifted through 
ASTM 60 mesh sieve (250 µ) and added extra granularly 
and lubricated for 3 min. The moisture content of the 
lubricated blend was determined by heating the sample 
in hot air oven (SMC-120, Spectrum Pvt. Ltd., Mumbai, 
India) at 105 °C. Compression was carried out using ten 
station single rotary tablet compression machine (Pilot 
Press Tablet Machine, Chamunda Pharma Machinery 
Pvt. Ltd., Ahmedabad, India) equipped with bevelled 
flat-faced punches of 9 mm diameter at a tablet weight 
of 350 mg.
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Development of ofloxacin sustained release (SR) 
tablets
Ofloxacin SR tablet formulations (F1–F8) were 
prepared by wet granulation technique as given in Table 
III. All the powders were passed through ASTM 40 mesh 
sieve (425 µ). Required quantities of ofloxacin and HPMC 
K100M were mixed thoroughly in double cone blender 
at 14 ± 2 rpm for 10 min. Avicel PH 101 and lactose 
monohydrate were added to the above blend and mixed 
for 5 min. The blend was granulated, using distilled water 
as a granulating fluid. After enough cohesiveness was 
obtained, the mass was sieved through ASTM 20 mesh 
sieve (850 µ). The granules were dried at 50 °C for 4 h and 
thereafter kept in desiccator for 6 h at room temperature. 
The granules were lubricated for 3 min with magnesium 
stearate (0.5 %w/w) and Aerosil 200 P (0.5%w/w) (ASTM 
60 mesh sifted). The moisture content of the lubricated 
granules was determined by heating the sample in hot 
air oven (SMC-120, Spectrum Pvt. Ltd., Mumbai, India) 
at 105 °C. The tablets were compressed at a weight of 550 
mg on pilot press tablet compression machine equipped 
with bevelled flat-faced punches 11 mm in diameter.
TABLE I - Physicochemical parameters of cefixime trihydrate and ofloxacin
Physicochemical Parameters Cefixime trihydrate Ofloxacin
Pharmacodynamics:
cefixime, an antibiotic, is a third-generation 
cephalosporin cefixime is highly stable in 
the presence of beta-lactamase enzymes. 
As a result, many organisms resistant to 
some cephalosporin due to the presence 
of beta-lactamases may be susceptible to 
cefixime. 
ofloxacin is a quinolone/fluoroquinolone 
antibiotic and its mode of action depends 
on blocking of bacterial DNA replication 
by binding itself to an enzyme called 
DNA gyrase, which allows the untwisting 
required replicating one DNA double helix 
into two. Notably the drug has 100 times 
higher affinity for bacterial DNA gyrase, 
ofloxacin is a broad-spectrum antibiotic.
Mechanism of action
cefixime binds to specific penicillin-
binding proteins (PBPs) located inside the 
bacterial cell wall, causing the inhibition of 
the third and last stage of bacterial cell wall 
synthesis. Cell lysis is then mediated by 
bacterial cell wall autolytic enzymes such 
as autolysins; it is possible that cefixime 
interferes with an autolysin inhibitor.
ofloxacin acts on DNA gyrase replication 
or transcription. By inhibiting their 
function, the drug thereby inhibits normal 
cell division.
Absorption About 40%-50% absorbed orally Bioavailability of ofloxacin in the tablet 
formulation is approximately 98%
Half life
 3-4 hours (may range up to 9 hours). 
In severe renal impairment (5 to 20 ml/
min creatinine clearance), the half-life 
increased to an average of 11.5 hours. 
 9 hours
TABLE II - Composition (%w/w) of cefixime trihydrate IR tablets (350 mg)
Sr. No. Ingredients C1 C2 C3 C4 C5 C6 C7 C8 C9
1 Cefixime trihydrate 57.14 57.14 57.14 57.14 57.14 57.14 57.14 57.14 57.14
2 Avicel PH 102 38.86 36.86 34.86 38.86 36.86 34.86 38.86 36.86 34.86
3 Glycolys 3 5 7 - - - - - -
4 Ac-Di-Sol - - - 3 5 7 - - -
5 Polyplasdone XL - - - - - - 3 5 7
6 Magnesium stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
7 Aerosil 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
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Evaluation of tablets
Prior to compression, lubricated blend of cefixime 
trihydrate IR tablets and granules of ofloxacin SR tablets 
were characterized for physical parameters like angle of 
repose, bulk and tapped densities and % compressibility 
[14, 15].The properties of the compressed tablets, such 
as thickness (Digital Vernier Caliper, Mitutoya Corp.), 
hardness (Mht-20, Monsanto Tablet Hardness Tester, 
Campbell Electronics, Mumbai, India), friability (EF-
1W, Electrolab Ltd., Mumbai, India), weight variation, 
and disintegration time (ED-2L, Electrolab Ltd., Mumbai, 
India) were evaluated. The content of cefixime trihydrate 
in tablets was determined as per the procedure specified 
in USP. However, ofloxacin in tablets was determined 
spectrophotometrically at 293 nm.
In vitro drug release studies
In vitro drug release studies of cefixime trihydrate 
IR tablets were carried out as per the specifications 
given in USP 30. The USP dissolution test apparatus 
type I (Veego Scientifics, Mumbai, India) at 100 rpm 
was used for studies. The dissolution medium consisted 
of 0.05 M potassium phosphate buffer pH 7.2 (900 
mL), maintained at 37 ± 0.5 °C. An aliquot (10 ml) was 
withdrawn at specific time intervals and drug content was 
determined by UV-visible spectrophotometer (Shimadzu 
1700 (E) 23, Japan) at 289 nm. The release profiles were 
compared with marketed formulation (ZIFI 200). The 
same conditions of in vitro dissolution as described for 
the studies of cefixime trihydrate IR tablets were used 
to study the in vitro drug release of ofloxacin SR tablets 
except the dissolution media used. The drug release of 
ofloxacin were determined under different dissolution 
media pH 1.2 acidic buffer for the first 2 h, pH 4.5 acetate 
buffer for next hour and phosphate buffer pH 7.4 from 4 
to 24 h. An aliquot (10 ml) was withdrawn at specific time 
intervals and drug content was determined by UV-visible 
spectrophotometer at 293 nm. Comparison of release 
profiles were carried out against marketed formulation 
(OF-OD). 
Drug release kinetic model
To describe the kinetics of drug release from 
the optimized ofloxacin SR tablets, mathematical 
models zero-order, first order, Higuchi, Hixon-crowell, 
Korsmeyer-Peppas were used. The criterion for selecting 
the best fit model was chosen on the basis of the goodness 
fit test. Equations previously stated were used to determine 
the best fit model for release kinetics (Costa, Lobo, 2001).
Formulation of cefixime trihydrate (IR) and 
ofloxacin (SR) bilayer tablets
Bilayer tablets were formulated with cefixime 
trihydrate as IR layer and ofloxacin as SR layer. The 
optimized cefixime trihydrate IR tablets and ofloxacin 
SR tablets (similar in release profiles with marketed 
formulations) were selected for the development of bilayer 
tablets. The sustained release blend of ofloxacin (550 
mg) was compressed lightly Pilot press tablet machine 
(Chamunda Pharma Machinery Pvt. Ltd., India) equipped 
with 19 mm caplet shape, bevelled and biconcave punches. 
Over this compressed layer, manually the immediate 
release layer of cefixime trihydrate (350mg) was placed 
and compressed to obtain hardness in the range of 5-6 kg/
cm2 to form a bilayered tablet.
Evaluation of bilayer tablets
The properties of the compressed tablets, such 
as thickness, hardness, friability, weight variation, 
disintegration time were evaluated. The content of 
cefixime trihydrate and ofloxacin in bilayer tablets was 
determined simultaneously by using high performance thin 
layer chromatography (HPTLC) (CAMAG Reprostar 3 
and TLC Scanner 3, CAMAG Scientific Inc., Wilmington, 
USA) at λmax 290 nm.
TABLE III - Composition (%w/w) of ofloxacin sustained release tablets (550 mg)
Sr. No. Ingredients F1 F2 F3 F4 F5 F6 F7 F8
1 Ofloxacin 72.73 72.73 72.73 72.73 72.73 72.73 72.73 72.73
2 HPMC K100M 8 10 12 15 10 10 10 10
3 Avicel PH 101 9.14 8.14 7.14 10.64 11.39 9.76 6.51 4.88
4 Lactose monohydrate 9.14 8.14 7.14 10.64 4.88 6.51 9.76 11.39
5 Magnesium stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
6 Aerosil 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Development and evaluation of bilayer tablets of combination of antibiotics for the treatment of sexually transmitted disease 559
In-vitro drug release studies of bilayer tablets
In-vitro dissolution studies of cefixime trihydrate 
and ofloxacin bilayer tablets were carried out separately 
as per the above described procedure. The withdrawn 
samples were analyzed simultaneously by HPTLC at λmax 
290 nm. The dissolution profiles were compared with 
marketed formulations, ZIFI 200 and OF-OD for cefixime 
trihydrate and ofloxacin respectively.
Stability studies
The study was done to know the effect of ageing 
and temperature on the physical parameters, drug content 
and in-vitro drug release. The bilayer tablets were packed 
in amber colored vials sealed with bromo butyl rubber 
stoppers and charged at accelerated stability condition 
of 40 ± 2 °C temperature and relative humidity of 75 ± 
5% in environmental stability chamber for the period of 
3 months.
RESULTS
The FT-IR spectra of physical mixture of drugs and 
drugs with excipients after 30 days of accelerated stability 
were compared (Figures 1 and 2). The spectra showed no 
additional peaks compared to their individual IR spectrum 
of initial conditions. Also the physical appearance of the 
samples was not changed.
The FT-IR spectra of cefixime trihydrate and 
ofloxacin have shown the presence of peaks which are 
characteristics of the drugs structures (Table IV). 
The granules of different formulations were 
evaluated with respect to angle of repose, bulk density, 
tapped density, compressibility index, moisture content 
and drug content. Moisture content was found in the 
range of 1.8 - 2.4%w/w. Other parameters for granules 
were found to be in the acceptable range. All the blends/
granules have shown good compression properties. 
Drug content was found to be uniform among different 
batches and was more than 95%. The compressed tablets 
were evaluated for weight variation, thickness, hardness, 
friability, disintegration time (for cefixime trihydrate IR 
tablets) and content. The weight of tablets from all the 
formulation batches was found within acceptable range 
of weight variation (±5 %) as per USP. The hardness of 
the tablets was found in the range of 4.0-7.0 kg/cm2. The 
disintegration time obtained for the cefixime trihydrate 
IR tablets was less than 1 min which was well below 
the limit of disintegration time of uncoated IR tablets 
as per the USP (i.e. not more than 15 min). The tablets 
containing Polyplasdone XL were disintegrated at 
faster rate as compared to the other disintegrants used. 
The tablets formulated using Polyplasdone XL at 5 and 
7%w/w concentration, disintegrated within 24 and 21 
s respectively. Since the disintegration time observed 
with Polyplasdone XL containing tablets was minimum, 
the batches (C8 and C9) were considered for further 
studies. However, similarity factor (f2) was taken into 
consideration for the ofloxacin SR tablets. The tablets were 
assayed and the drug content was found within the range 
of 90-110% as per USP specifications. Also the tablets 
complied with the friability test.
When drug release from various batches (C1-C9) 
containing various superdisintegrants in concentration of 
3, 5 and 7%w/w was compared, it was found that C8 and 
C9 batches containing Polyplasdone XL releases drug 
more promptly and completely within 30 min. So these 
batches were compared for drug release from reference 
product (ZIFI 200). From the in vitro drug release data 
(Figure 4), it can be seen that the drug release profile of 
tablets from C8 batch was matching completely with the 
ZIFI 200. However, the C9 batch released drug at faster 
rate. Hence, C8 batch formulation was considered as 
optimized and was used further for the development of 
bilayer tablets. 
Dissolution study data of ofloxacin SR tablets and 
OF-OD tablets demonstrated that increased concentration 
of HPMC K100M lead to the decreased release of 
ofloxacin. As the amount of lactose monohydrate was 
increased, drug release was also increased which may 
be due to the hydrophilic nature of lactose incorporated 
in the formulation. All the above studied parameters 
indicated that the batch F8 where lactose monohydrate 
and Avicel PH 101 were used in 1:4 ratio and HPMC in 
10%w/w concentration was found to be best suited for 
the formulation of SR layer in bilayer tablets (Figure 5) 
since it has the highest f2 value of 87.01 when compared 
with other formulation batches. Hence, F8 formulation 
was considered as optimized and used further for the 
development of bilayer tablets.
The optimized formulation batch (F8) has shown 
Korsmeyer-Peppas as a best fit drug release kinetic model 
(Table V). The release exponent value (n) was found to be 
0.7921. The dominant mechanism for drug release through 
matrix systems was found to be anomalous transport. The 
cefixime trihydrate (IR) and ofloxacin (SR) bilayer tablets 
were formulated using optimized batches C8 and F8. 
The physical parameters of evaluation of bilayer tablets 
are shown in Table VI All the physical parameters of the 
tablets were well within the range.
The Cefixime trihydrate IR layer of bilayer 
S. S. Gaikwad, S. A. Chafle, P. S. Morris, J. G. Avari560
FIGURE 1 - Infra red (FT-IR) spectrum of cefixime trihydrate and cefixime trihydrate with excipients.
tablets formulated from the blend of C8 formula 
have shown the disintegration time of 30 sec. In-vitro 
dissolution study of bilayer tablets were performed 
using USP type I apparatus (Table 7 & 8 show the 
percent drug release)and amount of drug released was 
calculated simultaneously using HPTLC (representative 
densitogram is shown in Figure 3).Cumulative % drug 
released as a function of time plotted for Cefixime 
trihydrate and Ofloxacin were compared with their 
marketed products (Figures 4 and 5). Three months of 
accelerated stability studies show no significant effect 
on the drug release profile (Figures 6 and 7).The other 
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FIGURE 2 - Infra red (FT-IR) spectrum of ofloxacin and ofloxacin with excipients.
physical parameters were also found to be stable after a 
three month stability study (Table IX).
DISCUSSION
The FT-IR spectrum confirms that no interaction 
was observed between drug-drug as well as drugs with 
disintegrants, microcrystalline cellulose and HPMC, 
which were used in the development of the formulations. 
The values of angle of repose indicated satisfactory 
flow behavior. It is considered that the disintegration 
is the first step in the dissolution of immediate release 
S. S. Gaikwad, S. A. Chafle, P. S. Morris, J. G. Avari562
TABLE IV - Drug characterization by IR-Spectroscopy
Sr. No.
Drug characterization of cefixime trihydrate Drug characterization of ofloxacin
Wave number (cm-1) Functional group Wave number (cm-1) Functional group
1 3588.0 , 3568.7 primary and secondary amines 3022.0 alkene group
2 2519.3 nitrile group 2999.7 aromatic rings
3 1772 carboxylic acid 1624.3 aryl carboxylic acid
4 1336 Lactum. 1523 halogen compound C-F
FIGURE 3 - Representative densitogram of mixed standard solution of ofloxacin (200 ng/band, Rf = 0.61 ± 0.10) and cefixime 
trihydrate (200 ng/band, Rf = 0.78 ± 0.12).
FIGURE 4 - Cumulative percentage of cefixime trihydrate 
released versus time (50 min) in pH 7.2 phosphate buffer, 900 
ml at 100 rpm using USP type I dissolution test apparatus (mean 
± SD, n= 6). C8F8 (Initial), data of initial condition and ZIFI 
200, marketed reference product.
tablets. Relating friability, disintegration time and rate 
of dissolution parameters, it was observed that increase 
in friability does not affect much disintegration time of 
tablets, that may be due to the use of superdisintegrants. 
Moisture content indicated optimum drying of granules. 
Korsmeyer-Peppas release kinetic model was found to 
be the best fit drug release kinetic model for F8 batch 
which states that the release mechanism is not well 
known or more than one type of release phenomena could 
be involved. The dissolution study suggested that the 
cefixime trihydrate immediate release layer has released 
more than 85% of drug within 10 min which was desired 
and was matching in release profile with the reference 
product. The complete release was observed within 30 
min of the dissolution study. The release of ofloxacin from 
SR layer of bilayer tablets was also compared with the 
reference product (OZ-OD). The initial similarity factor 
(f2) value was found to be close with similarity factor (f2) 
value after stability study.
The evaluation of physical parameters of tested 
batches has not shown any significant effect after 3 months 
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of accelerated stability studies (Figures 6 and 7). The drug 
content of the bilayer tablets was also found to be within 
the specification of USP. The batches also have not shown 
differences in the drug release profiles. Hence, it can be 
concluded that the formulated bilayer tablets were stable 
for the given condition and period of stability. 
The combination of cefixime and ofloxacin has 
been documented to have dual mode of action. Ofloxacin 
prevents nucleic acid synthesis and cefixime inhibits 
cell wall synthesis, hence less chance for microbes to 
develop resistance against combination of antibiotics 
cefixime trihydrate showed similar release profiles in-
vitro under acidic conditions to those of the immediate 
release cefixime trihydrate tablets (ZIFI 200) developed 
TABLE V - Drug release models for optimized batch
REGRESSION COEFFICIENT
Formulation 
Code
Zero order 
plots
(r2)
First order 
plots
(r2)
Higuchi 
plots
(r2)
Korsemeyer-
peppas plots
(r2)
Hixson-crowells 
plots
(r2)
Slope
(n)
F8 0.9792 0.9385 0.9189 0.9826 0.9786 0.7912
TABLE VI - Evaluation parameters of bilayer tablets
Parameters
Weight variation 
(%)
Thickness 
(mm)
Hardness 
(kg/cm²)
Friability 
(%)
Content uniformity (%)
Cefixime 
trihydrate Ofloxacin
C8F8 ± 4.27 7.8 ± 0.08 5-6 0.14 99.54 ± 0.45 98.25 ± 1.65
FIGURE 7 - In vitro drug release study of ofloxacin from bilayer 
tablets before and after 3 months.
FIGURE 6 - In vitro drug release study of cefixime trihydrate 
from bilayer tablets before and after 3 months.FIGURE 5 - Cumulative percentage of ofloxacin released versus 
time (hour) in pH 1.2 buffer for 2 hour, pH 4.5 acetate buffer 
for next hour and pH 7.4 phosphate buffer 900 ml at 100 rpm 
using USP type I dissolution test apparatus (mean ± SD, n= 6) 
for remaining hours. C8F8 (Initial), data of initial condition and 
OF-OD, marketed reference product.
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by an Indian company. Ofloxacin sustained release layeron 
the other hand showed an improvementin the release of 
ofloxacin in vitro compared with that of ofloxacin SR 
tablets (OF-OD). This release profile is beneficial, as 
it releases cefixime immediately for faster action and 
ofloxacin slowly for the longer duration of time to maintain 
a steady state concentration of drug in blood.
Formulating cefixime trihydrate as immediate 
release and ofloxacin as sustained release layer in a bilayer 
tablet reduces the frequency of administration and dose 
of the drugs. Reduced dose of the drug automatically will 
tend to reduce the adverse effect of the drug.
Successful bilayer tablet formulation containing the 
antibiotics cefixime trihydrate ofloxacin were developed 
for once a day administration for treatment of sexually 
transmitted diseases.
CONCLUSION
Thus from the result, it can be concluded that the 
bilayer tablets containing 200 mg of cefixime trihydrate 
as immediate release component and 400 mg ofloxacin as 
sustained release component has successfully developed. 
Also, the release from the developed formulations was 
comparable to the marketed drug formulations. The 
developed bilayer tablets were stable in the accelerated 
stability conditions. The results of current study clearly 
show that bilayer tablet was developed as a stable dosage 
form. cefixime trihydrate and ofloxacin bilayer tablet has 
a promising potential as an alternative to the conventional 
dosage form. This new dosage form has commercial 
marketing potency as no such delivery systems are 
presently available in market.
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TABLE VII - Dissolution data of cefixime trihydrate in bilayer 
tablets
Time (min) C8F8
0 0
10 87.52±0.43
20 89.57±0.51
30 99.53±0.49
40 99.42±0.44
50 99.55±0.51
TABLE VIII - Dissolution data of ofloxacin in bilayer tablets 
(n = 3)
Time (h) C8F8
1 15.69±1.18
2 25.24±1.21
3 34.68±1.11
4 38.79±1.02
5 41.52±1.05
6 46.77±0.95
7 52.49±1.28
8 56.22±1.42
9 62.63±1.20
10 71.25±1.15
24 99.63±1.19
TABLE IX - Evaluation parameters of stability batch (C8F8)
Evaluation parameters
Before stability 
storage
After 1 month 
storage
After 2 months 
Storage
After 3 months 
storage
Hardness (kg/cm2) 5-6 6 ± 1.1 5.8 ± 1.6 5.5 ± 1.1
Friability (%) 0.136 0.5 ± 0.6 0.6 ± 0.3 0.6 ± 0.4
Weight variation (%) 4.2 2.4 2.7 3.0
Disintegrating time of cefixime trihydrate layer 
in seconds
25 24± 1 21± 2 23± 1
Drug content (%) 99.54±0.45 97.04 ± 1.8 96.89 ± 2.0 96.80 ± 2.4
% drug release of (cefixime layer ) 98.25±1.65 97.98 ± .2.7 97.87 ± 3.2 95.69 ± 2.1
% drug release of (ofloxacin layer ) at the end 
of 24hr
99.55±0.51 97.05±1.9 96.77±1.4 96.11±1.8
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